Professor Ciechanover is a physician and biologist and conducts research at the Technion – Israel Institute of Technology in Haifa. AvH in Germany awards this prize to internationally renowned scientists and scholars in recognition of their entire achievements to date, and whose fundamental discoveries, theories, or insights have had a significant impact on their discipline. The award is valued at 60,000 euros.
At the MDC Professor Ciechanover will cooperate in particular with the research group led by Professor Thomas Sommer. There he will work in joint projects on the disposal of misfolded proteins. This cooperation will enable the MDC to intensify its contacts with Israeli scientists and in particular with the Technion.
Professor Ciechanover is one of the discoverers of the ubiquitin-proteasome system for regulated protein degradation. One of the main functions of the system is waste disposal. In 2004 he shared the Nobel Prize in Chemistry for this discovery with Avram Hershko and Irwin Rose. This quality control maintenance system selectively disposes misfolded/denatured/inactive proteins that, if accumulated, can cause cellular damage. Thus, only proteins that are marked with ubiquitin are recognized and enter the proteasome, the molecular shredder of the cell. There they are chopped into pieces and degraded. Ubiquitin, as the name (ubiquitous) implies, is present in all eukaryotic (nucleated) cells.
Aberrations in this cellular waste disposal machinery can lead to a wide array of diseases, ranging from cancer to neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease, genetic diseases such as cystic fibrosis, and disorders of the immune system. The research on the ubiquitin-proteasome system and the identification of the components involved in the degradation of key proteins has already led to the development of a new cancer drug. Aaron Ciechanover is convinced that this research will lead to the development of many additional drugs that will selectively target only proteins that are involved in a specific disease process.
Aaron Ciechanover was born in Haifa, Israel in 1947. He received his MD degree from Hebrew University of Jerusalem in 1975, and his PhD in Biology from Technion in 1982. He is currently Distinguished Professor at the Cancer and Vascular Biology Research Center in the Rappaport Research Institute and Faculty of Medicine, Technion – Israel Institute of Technology. Prior to receiving the Nobel Prize he was a recipient of the 2000 Albert Lasker Award and the 2003 Israel Prize. He is a member of the Israeli Academy of Sciences and Humanities, and the National Academy of Sciences of the USA (Foreign Member).
Barbara Bachtler | Max-Delbrück-Centrum
Starting Grants awarded to 27 young researchers
21.11.2014 | Schweizerischer Nationalfonds SNF
Chips für die Kommunikationstechnik der Zukunft
12.11.2014 | Stifterverband für die Deutsche Wissenschaft
21.11.2014 | Event News
13.11.2014 | Event News
12.11.2014 | Event News
21.11.2014 | Earth Sciences
21.11.2014 | Life Sciences
21.11.2014 | Press release